

ASX ANNOUNCEMENT

COMMERCIAL COLLABORATION TO INTRODUCE THE FERRISCAN TEST IN UK

Resonance Health is pleased to announce a commercial collaboration between its subsidiary Inner Vision Biometrics Pty Ltd (“IVB”) and MedTel UK Ltd, a division of the international radiology group Med-Tel International Corporation. Med-Tel is a leading international owner and operator of diagnostic imaging centres operating out of 22 centres in the U.S. and 6 in the U.K.

Med-Tel and IVB will cooperate in the introduction of the FerriScan test in the U.K. market. FerriScan is a novel non invasive test for iron overload in the body developed by IVB which utilizes magnetic resonance imaging (MRI) technology. Iron overload diseases are amongst the most common genetic disorders and are a significant cause of mortality around the world. An estimated 500,000 to 4 million people in the U.K. have elevated blood iron levels and may benefit from the use of FerriScan to accurately determine their liver iron loading.

The proposed collaboration between MedTel and IVB will commence in April 2004 in anticipation of U.K. regulatory approval of FerriScan in the second half of the year. The collaboration will enable IVB to prepare for the U.K. launch of FerriScan with an experienced industry partner whilst providing MedTel with a first mover advantage in offering the FerriScan service through its City of London Medical Centre. The collaboration will include cooperation in technical and regulatory affairs, in organizing on-going clinical evaluations, in the preparation of U.K. medical marketing materials, presentation of FerriScan to U.K. medical practitioners, and in liaison with private health insurers and the NHS regarding reimbursement for the test.

“Since its inception over ten years ago, the MedTel Group has developed leading-edge expertise in recording and securely transmitting MRI images over large distances. MedTel is an ideal commercial partner in this regard as the FerriScan service will involve scans from U.K. patients being transmitted and then analysed at IVB’s facility in Western Australia”, Resonance’s managing director Tony Fitzgerald said.

“Our collaboration with MedTel in the U.K. is an important first step in the international launch of FerriScan and will assist IVB to prepare for broader initiatives elsewhere in Europe and the U.S. in 2005”, Mr Fitzgerald said.

For further information:	
Media / investor relations	Company
Rebecca Christie, Buchan (02) 9293 2836 0417 382 391 rchristie@bcg.com.au	Mr Tony Fitzgerald, Managing Director Resonance Health Limited (08) 9389 5933 0418 903 647 tfitzgerald@resonancehealth.com